Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-05T04:10:18.521Z Has data issue: false hasContentIssue false
  • English
  • Français

Co-phenylcaine Forte spray: innovative ways of minimising cost

Published online by Cambridge University Press:  29 October 2013

A Gungadeen ,
Y Ramakrishnan  and
H C Cocks
A Gungadeen*
Affiliation:
Department of Otolaryngology, City Hospitals Sunderland NHS Foundation Trust, UK
Y Ramakrishnan
Affiliation:
Department of Otolaryngology, City Hospitals Sunderland NHS Foundation Trust, UK
H C Cocks
Affiliation:
Department of Otolaryngology, City Hospitals Sunderland NHS Foundation Trust, UK
*
Address for correspondence: Mr A Gungadeen, Department of Otolaryngology, City Hospitals Sunderland, Kayll Road, Sunderland, SR4 7TP E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To investigate whether multiple-use Co-phenylcaine Forte® spray was more cost-effective than single-use vials.

Methods:

A literature review was conducted to determine the risk of cross-contamination associated with multiple-use topical nasal anaesthetic spray. The costs of multiple-use Co-phenylcaine Forte and single-use co-phenylcaine were compared, and potential savings were calculated. The cost of procuring these drugs from other sources was also examined.

Results:

Switching to multiple-use Co-phenylcaine Forte spray would lead to at least 40 per cent savings if bought from our local retailer. Potential savings of more than 70 per cent could be made if the drugs were procured from sources other than our local distributor.

Conclusion:

Multiple-use Co-phenylcaine Forte spray is safe to use and more cost-effective than single-use vials. This paper illustrates how money can be saved within the National Health Service through changes in drug procurement. Similar cost savings to those calculated for our department could be made in other ENT departments nationally, depending on their annual consumption of co-phenylcaine.

Keywords

Phenylephrine, Lidocaine Drug CombinationCophenylcaineEpistaxisCost SavingsNational Health Policy
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 127 , Issue 11 , November 2013 , pp. 1103 - 1105
Copyright
Copyright © JLO (1984) Limited 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Douglas, R, Hawke, L, Wormald, P-J. Topical anaesthesia before nasendoscopy: a randomised controlled trial of co-phenylcaine compared with lignocaine. Clin Otolaryngol 2006;31:33–5CrossRefGoogle ScholarPubMed
2Rashid, M, Karagama, YG. Study of microbial spread when using multiple-use nasal anaesthetic spray. Rhinology 2011;49:281–5CrossRefGoogle ScholarPubMed
3ENT Technologies Ltd Online. In: http://www.enttech.com.au/products/co-phenylcaine-forte [6 January 2013]Google Scholar
4Pharmacy Online. In: http://www.pharmacyonline.com.au/co-phenylcaine-forte-spray-50ml [6 January 2013]Google Scholar